Tolvaptan in portal hypertension: real life experience

Tolvaptan (TVP) is a selective antagonist of vasopressin receptors, approved for the treatment of hyponatremia in SIADH, congestive heart failure (CHF) and cirrhosis. We retrospectively reviewed all cases where TVP was used in a tertiary hospital (January 2012- January 2017). Our aim was to study th...

Full description

Bibliographic Details

Published in:	Revista española de enfermedades digestivas Vol. 115; no. 4; p. 206
Main Authors:	Tejedor, Marta, Delgado, Agustín, Melero, Rosa, Fernández-Alonso, Víctor, Salcedo, Magdalena, Rodríguez-Benítez, Patrocinio
Format:	Journal Article
Language:	English
Published:	Spain 01-04-2023
Subjects:	Antidiuretic Hormone Receptor Antagonists - therapeutic use Benzazepines - therapeutic use Humans Hypertension, Portal - complications Hypertension, Portal - drug therapy Hyponatremia - chemically induced Hyponatremia - etiology Retrospective Studies Tolvaptan - therapeutic use
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!